Shattuck Labs Exercises 50.6M Warrants Generating $54.9M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 22 hours ago
0mins
Source: seekingalpha
- Warrant Exercise Overview: Shattuck Labs has received notices to exercise approximately 50.6 million warrants, which represents 96% of those issued in its August 2025 private placement, and is expected to generate around $54.9 million in gross proceeds, significantly enhancing its liquidity.
- Future Cash Inflows: As of March 31, 2026, the company had already received $5.6 million from the exercise of about 5.15 million warrants, and it anticipates an additional $49.3 million from approximately 45.44 million warrants, further solidifying its financial foundation.
- Cash Reserves Status: Shattuck Labs reported $90.4 million in cash, cash equivalents, and short-term investments as of March 31, 2026, and with the expected warrant proceeds, the company projects it can sustain operations into 2029, indicating strong financial health.
- Strategic Fund Utilization: The exercise of these warrants not only bolsters Shattuck Labs' financial strength but also secures funding for future R&D and operations, further advancing its strategic development in the biotechnology sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STTK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STTK
Wall Street analysts forecast STTK stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 3.900
Low
4.00
Averages
8.33
High
15.00
Current: 3.900
Low
4.00
Averages
8.33
High
15.00
About STTK
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Shattuck Labs Exercises 50.6M Warrants Generating $54.9M
- Warrant Exercise Overview: Shattuck Labs has received notices to exercise approximately 50.6 million warrants, which represents 96% of those issued in its August 2025 private placement, and is expected to generate around $54.9 million in gross proceeds, significantly enhancing its liquidity.
- Future Cash Inflows: As of March 31, 2026, the company had already received $5.6 million from the exercise of about 5.15 million warrants, and it anticipates an additional $49.3 million from approximately 45.44 million warrants, further solidifying its financial foundation.
- Cash Reserves Status: Shattuck Labs reported $90.4 million in cash, cash equivalents, and short-term investments as of March 31, 2026, and with the expected warrant proceeds, the company projects it can sustain operations into 2029, indicating strong financial health.
- Strategic Fund Utilization: The exercise of these warrants not only bolsters Shattuck Labs' financial strength but also secures funding for future R&D and operations, further advancing its strategic development in the biotechnology sector.
See More
Shattuck Labs Prices Public Offering to Raise $75M
- Funding Size: Shattuck Labs has priced its public offering at $4.00 per share for approximately 10.88 million shares, aiming to raise around $75 million to support the advancement of its clinical programs, particularly focusing on DR3 blocking antibodies for inflammatory and immune-mediated diseases.
- Warrant Issuance: The company is also issuing pre-funded warrants to purchase about 7.87 million shares at a price of $3.9999 per warrant, a strategy designed to attract more investors and enhance liquidity.
- Underwriter Option: The underwriters have a 30-day option to purchase an additional 2.81 million shares, providing flexibility that could offer the company further financial support and enhance its financial stability.
- Stock Price Fluctuation: Following the public offering announcement, Shattuck Labs' stock price fell over 6% during pre-market trading on Wednesday, reflecting market caution regarding the company's financing plans, which may impact investor confidence in the short term.
See More
Shattuck Labs Prices Public Offering at $4 per Share
- Public Offering Details: Shattuck Labs has priced its public offering at $4 per share for 10.88 million shares, expecting gross proceeds of approximately $75 million, indicating a proactive financing strategy in the capital markets.
- Pre-Funded Warrants: The company is also offering pre-funded warrants to purchase up to 7.87 million shares at $3.9999 each, enhancing investor participation and interest in the offering.
- Underwriter Team: The offering is managed by Leerink Partners, J.P. Morgan, Piper Sandler, and Cantor, reflecting strong market confidence in Shattuck Labs' prospects.
- Stock Performance Volatility: STTK has traded between $0.71 and $8.33 over the past year, closing at $4.27, although it has seen a pre-market decline of 4.92%, indicating some volatility but overall market resilience.
See More
Shattuck Labs Prices Public Offering at $4.00 per Share
- Offering Size: Shattuck Labs announced a public offering of 10,879,376 shares at a price of $4.00 per share, with expected gross proceeds of approximately $75 million, indicating strong demand in the capital markets.
- Pre-Funded Warrants: The company is also offering pre-funded warrants to purchase up to 7,870,624 shares at $3.9999 each, with an exercise price of just $0.0001, enhancing investor participation and interest.
- Underwriter Option: Shattuck has granted underwriters a 30-day option to purchase an additional 2,812,500 shares at the public offering price, reflecting confidence in market demand and providing flexibility for future financing.
- Expected Closing: The offering is anticipated to close on June 11, 2026, subject to customary closing conditions, which, if successful, will provide crucial funding for the company's ongoing research and development efforts.
See More
Shattuck Labs Initiates Public Offering of Common Stock
- Public Offering Launch: Shattuck Labs (STTK) has commenced a public offering of common stock or pre-funded warrants for certain investors, indicating the company's proactive approach in capital markets.
- Underwriter Option: The company expects to grant underwriters a 30-day option to purchase up to an additional 15% of common stock, a strategy aimed at enhancing fundraising capabilities and reducing financing costs.
- Stock Price Volatility: Following the public offering announcement, STTK's stock price fell 15.69% to $3.60 in after-hours trading, reflecting market caution regarding the offering.
- Funding Continuation: Shattuck Labs recently secured $54.9 million from warrant exercises, extending its cash runway into 2029, demonstrating a proactive strategy in financial management.
See More
Shattuck Labs Initiates Public Offering of Common Stock
- Public Offering Launch: Shattuck Labs has announced the initiation of a public offering to issue common stock or pre-funded warrants to select investors, indicating the company's proactive stance in capital markets aimed at raising funds for its R&D projects.
- Underwriter Selection: The offering is being managed by prominent financial institutions including Leerink Partners, J.P. Morgan, Piper Sandler, and Cantor, which enhances market confidence in the company's financing activities through the involvement of reputable underwriters.
- Additional Share Option: Shattuck expects to grant underwriters a 30-day option to purchase up to an additional 15% of shares, a strategy that could increase the offering size if demand is strong, thereby providing the company with greater financial flexibility.
- Market Condition Uncertainty: The completion timing and size of the public offering remain uncertain and are subject to market and other conditions, reflecting the company's cautious approach in the current economic environment while signaling investors to stay alert to market developments.
See More
Shattuck Labs Exercises 50.6M Warrants Generating $54.9M
- Warrant Exercise Overview: Shattuck Labs has received notices to exercise approximately 50.6 million warrants, which represents 96% of those issued in its August 2025 private placement, and is expected to generate around $54.9 million in gross proceeds, significantly enhancing its liquidity.
- Future Cash Inflows: As of March 31, 2026, the company had already received $5.6 million from the exercise of about 5.15 million warrants, and it anticipates an additional $49.3 million from approximately 45.44 million warrants, further solidifying its financial foundation.
- Cash Reserves Status: Shattuck Labs reported $90.4 million in cash, cash equivalents, and short-term investments as of March 31, 2026, and with the expected warrant proceeds, the company projects it can sustain operations into 2029, indicating strong financial health.
- Strategic Fund Utilization: The exercise of these warrants not only bolsters Shattuck Labs' financial strength but also secures funding for future R&D and operations, further advancing its strategic development in the biotechnology sector.
See More
Shattuck Labs Prices Public Offering to Raise $75M
- Funding Size: Shattuck Labs has priced its public offering at $4.00 per share for approximately 10.88 million shares, aiming to raise around $75 million to support the advancement of its clinical programs, particularly focusing on DR3 blocking antibodies for inflammatory and immune-mediated diseases.
- Warrant Issuance: The company is also issuing pre-funded warrants to purchase about 7.87 million shares at a price of $3.9999 per warrant, a strategy designed to attract more investors and enhance liquidity.
- Underwriter Option: The underwriters have a 30-day option to purchase an additional 2.81 million shares, providing flexibility that could offer the company further financial support and enhance its financial stability.
- Stock Price Fluctuation: Following the public offering announcement, Shattuck Labs' stock price fell over 6% during pre-market trading on Wednesday, reflecting market caution regarding the company's financing plans, which may impact investor confidence in the short term.
See More
Shattuck Labs Prices Public Offering at $4 per Share
- Public Offering Details: Shattuck Labs has priced its public offering at $4 per share for 10.88 million shares, expecting gross proceeds of approximately $75 million, indicating a proactive financing strategy in the capital markets.
- Pre-Funded Warrants: The company is also offering pre-funded warrants to purchase up to 7.87 million shares at $3.9999 each, enhancing investor participation and interest in the offering.
- Underwriter Team: The offering is managed by Leerink Partners, J.P. Morgan, Piper Sandler, and Cantor, reflecting strong market confidence in Shattuck Labs' prospects.
- Stock Performance Volatility: STTK has traded between $0.71 and $8.33 over the past year, closing at $4.27, although it has seen a pre-market decline of 4.92%, indicating some volatility but overall market resilience.
See More
Shattuck Labs Prices Public Offering at $4.00 per Share
- Offering Size: Shattuck Labs announced a public offering of 10,879,376 shares at a price of $4.00 per share, with expected gross proceeds of approximately $75 million, indicating strong demand in the capital markets.
- Pre-Funded Warrants: The company is also offering pre-funded warrants to purchase up to 7,870,624 shares at $3.9999 each, with an exercise price of just $0.0001, enhancing investor participation and interest.
- Underwriter Option: Shattuck has granted underwriters a 30-day option to purchase an additional 2,812,500 shares at the public offering price, reflecting confidence in market demand and providing flexibility for future financing.
- Expected Closing: The offering is anticipated to close on June 11, 2026, subject to customary closing conditions, which, if successful, will provide crucial funding for the company's ongoing research and development efforts.
See More
Shattuck Labs Initiates Public Offering of Common Stock
- Public Offering Launch: Shattuck Labs (STTK) has commenced a public offering of common stock or pre-funded warrants for certain investors, indicating the company's proactive approach in capital markets.
- Underwriter Option: The company expects to grant underwriters a 30-day option to purchase up to an additional 15% of common stock, a strategy aimed at enhancing fundraising capabilities and reducing financing costs.
- Stock Price Volatility: Following the public offering announcement, STTK's stock price fell 15.69% to $3.60 in after-hours trading, reflecting market caution regarding the offering.
- Funding Continuation: Shattuck Labs recently secured $54.9 million from warrant exercises, extending its cash runway into 2029, demonstrating a proactive strategy in financial management.
See More
Shattuck Labs Initiates Public Offering of Common Stock
- Public Offering Launch: Shattuck Labs has announced the initiation of a public offering to issue common stock or pre-funded warrants to select investors, indicating the company's proactive stance in capital markets aimed at raising funds for its R&D projects.
- Underwriter Selection: The offering is being managed by prominent financial institutions including Leerink Partners, J.P. Morgan, Piper Sandler, and Cantor, which enhances market confidence in the company's financing activities through the involvement of reputable underwriters.
- Additional Share Option: Shattuck expects to grant underwriters a 30-day option to purchase up to an additional 15% of shares, a strategy that could increase the offering size if demand is strong, thereby providing the company with greater financial flexibility.
- Market Condition Uncertainty: The completion timing and size of the public offering remain uncertain and are subject to market and other conditions, reflecting the company's cautious approach in the current economic environment while signaling investors to stay alert to market developments.
See More
